ATE510013T1 - Verfahren und verwendungen von linker enthaltenden polypeptidliganden - Google Patents

Verfahren und verwendungen von linker enthaltenden polypeptidliganden

Info

Publication number
ATE510013T1
ATE510013T1 AT05759242T AT05759242T ATE510013T1 AT E510013 T1 ATE510013 T1 AT E510013T1 AT 05759242 T AT05759242 T AT 05759242T AT 05759242 T AT05759242 T AT 05759242T AT E510013 T1 ATE510013 T1 AT E510013T1
Authority
AT
Austria
Prior art keywords
binding
molecule
affinity
target
site
Prior art date
Application number
AT05759242T
Other languages
English (en)
Inventor
Feng Ni
Dmitri Tolkatchev
Zhengding Su
Original Assignee
Ca Nat Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ca Nat Research Council filed Critical Ca Nat Research Council
Application granted granted Critical
Publication of ATE510013T1 publication Critical patent/ATE510013T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C07K14/40—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts from Candida
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
AT05759242T 2004-06-23 2005-06-20 Verfahren und verwendungen von linker enthaltenden polypeptidliganden ATE510013T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58170304P 2004-06-23 2004-06-23
PCT/CA2005/000951 WO2006000081A1 (en) 2004-06-23 2005-06-20 Polypeptide ligands containing linkers

Publications (1)

Publication Number Publication Date
ATE510013T1 true ATE510013T1 (de) 2011-06-15

Family

ID=35781537

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05759242T ATE510013T1 (de) 2004-06-23 2005-06-20 Verfahren und verwendungen von linker enthaltenden polypeptidliganden

Country Status (5)

Country Link
US (1) US8063018B2 (de)
EP (1) EP1766011B1 (de)
AT (1) ATE510013T1 (de)
CA (1) CA2571815A1 (de)
WO (1) WO2006000081A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101094867B (zh) 2004-10-19 2011-08-24 隆萨股份公司 用于固相肽合成的方法
US20120094271A1 (en) * 2008-09-04 2012-04-19 Arizona Board Of Regents For And On Behalf Of Arizona State University Selecting for cooperatively interacting molecules
WO2010135277A2 (en) * 2009-05-18 2010-11-25 Brown University Cyclic-glur6 analogs, methods of treatment and use
WO2011159913A2 (en) * 2010-06-16 2011-12-22 The Trustees Of Dartmouth College Magnetic particle heating system and method for occlusion of the fallopian tube
US10155802B2 (en) * 2011-04-20 2018-12-18 National Research Council Of Canada Locally-active anticoagulants and anti-inflammatory agents
US20160168210A1 (en) * 2012-10-19 2016-06-16 National Research Council Of Canada Derivatives of collagen-binding hairpin peptides
US9545383B2 (en) 2014-04-01 2017-01-17 Massachusetts Institute Of Technology Blood clotting control
IL234246A0 (en) * 2014-08-21 2014-11-30 Omrix Biopharmaceuticals Ltd Stabilized thrombin
JP7590873B2 (ja) 2018-02-20 2024-11-27 パヴォニス ダイアグノスティクス インコーポレイテッド 酸化アルミニウム表面及び界面分子

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006128A1 (en) * 1988-12-05 1990-06-14 Biogen, Inc. Methods and compositions for inhibiting platelet aggregation
US5443827A (en) * 1993-05-03 1995-08-22 President And Fellows Of Harvard College Fibrin-targeted inhibitors of thrombin
WO1995011921A1 (en) * 1993-10-25 1995-05-04 National Research Council Of Canada Bivalent thrombin inhibitors
DE4404168A1 (de) * 1994-02-10 1995-08-17 Hoechst Ag Hirudinderivate und Verfahren zu deren Herstellung
AU4326397A (en) * 1996-07-09 1998-02-10 Bio-Technical Resources Novel arylsulfotransferase
EP1056413A4 (de) * 1998-02-27 2003-08-20 Bioelastics Res Ltd Injizierbare implantate zur vergrösserung und wiederherstellung von gewebe
AU2003201554A1 (en) * 2002-01-11 2003-07-24 National Research Council Of Canada Quantitative ranking of transient ligand binding to target biomolecules
WO2004076484A1 (en) * 2003-02-27 2004-09-10 National Research Council Of Canada Peptide inhibitors of thrombin as potent anticoagulants

Also Published As

Publication number Publication date
EP1766011B1 (de) 2011-05-18
US20090105116A1 (en) 2009-04-23
EP1766011A4 (de) 2009-06-24
EP1766011A1 (de) 2007-03-28
CA2571815A1 (en) 2006-01-05
US8063018B2 (en) 2011-11-22
WO2006000081A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
EP1545582A4 (de) Von amyolid-beta abgeleitete diffundierbare liganden (addls), addl-ersatzstoffe, addl-bindungsmoleküle und verwendungen davon
DK1503800T3 (da) Behandling og forebyggelse af vævsskade associeret med forøget C-reaktiv-protein produktion
EP1864998A3 (de) Bindungsmoleküle
HRP20230761T1 (hr) Gdf zamke
ATE440619T1 (de) Gerinnungsfaktor-fc chimere proteine zur behandlung von hämophilie
ATE555202T1 (de) Verfahren zur lieferung von rna-interferenz und verwendungen damit
WO2006023831A3 (en) Sequential protein isolation and purification schemes by affinity chromatography
UA95438C2 (ru) Биспецифические антитела, которые замещают функциональные белки
WO2008036406A3 (en) Compositions and methods related to protein displacement therapy for myotonic distrophy
DE602006020715D1 (de) Multiplex-assays für verzweigtkettige dna
WO2004093894A8 (en) Use of b7-h3 as an immunoregulatory agent
ATE485844T1 (de) Einwegvorrichtung zur diffusion von flüchtigen substanzen
BRPI0209933B8 (pt) proteína de fusão, e, molécula de ácido nucleico
ATE480643T1 (de) Homogener nachweis von analyten
EP1766011A4 (de) Linker enthaltende polypeptidliganden
ATE311444T1 (de) Verbesserungen in bezug auf ribosom-komplexe als selektionspartikel
WO2007094005A3 (en) Molecules and methods of using same for treating ccr5/ccr5 ligands associated diseases
EA200870244A1 (ru) Слитые белки rage и способы применения
DE60235467D1 (de) Emissionsarmer einkomponentige klebstoff
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
ATE495442T1 (de) Zusammensetzungen und verfahren zur erkennung von sirolimus
WO2008003707A3 (en) Minimized small peptides with high affinity for factor viii and factor viii-like proteins
EP2083018A3 (de) Zusammensetzungen und Verfahren mit Bezug zu STOP-1
BRPI0507918A (pt) processo para a carbonilação de compostos insaturados, composição de catalisador, e, ligando de difosfina bidentado assimétrico
DE502005000428D1 (de) Verfahren zur Herstellung von 1,2-Diaminocyclohexan-Platin(II)-Komplexen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties